Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial-Reference-Cited by-同舟云学术

Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial

Published:2018-08 Issue:8 Volume:24 Page:900-907
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Blanco J.R.,Alejos B.,Moreno S.

Funder

SPANISH AIDS Research Network

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference41 articles.

1. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression;Moore;Clin Infect Dis,2007

2. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation;Wada;AIDS,2015

3. For timing of HAART is less more? CD4+/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features;Fogli;New Microbiol,2014

4. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1;Fahey;N Engl J Med,1990

5. Hodgkin lymphoma in the swiss HIV cohort study;Clifford;Blood,2009

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunological Effects of Integrase Inhibitors as Part of Initial Therapy in People Living with HIV: A Systematic Literature Review;IATREIA;2024

2. CD4/CD8 Ratio Recovered as a Predictor of Decreased Liver Damage in Adults Infected With HIV: 16-Year Observational Cohort Study;JMIR Public Health and Surveillance;2024-01-09

3. Efectos inmunológicos de los inhibidores de integrasa versus inhibidores de la proteasa y de la transcriptasa reversa no nucleótidos como parte de la terapia de inicio en personas viviendo con VIH. Una revisión sistemática de la literatura;Iatreia;2024

4. Alteration in Gut Microbiome and Intestinal Barrier Function caused by Efavirenz versus Dolutegravir Treatments in Mice;2023-11-03

5. Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV;AIDS;2023-08-23